Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that at the Company's Annual General Meeting, held earlier today, all resolutions were passed on a show of hands. The proxy votes received from shareholders on each resolution are set out below.
Resolutions
Votes for
*
%
Votes against
%
Votes total
**
Votes withheld
***
Resolution 1
236,549,625
99.99
13,361
0.01
236,562,986
300,000
Resolution 2
236,275,612
100.00
1,240
0.00
236,276,852
586,134
Resolution 3
236,158,555
99.98
41,763
0.02
236,200,318
662,668
Resolution 4
236,275,612
100.00
1,240
0.00
236,276,852
586,134
Resolution 5
234,736,711
99.33
1,592,616
0.67
236,329,327
533,659
Resolution 6
231,213,811
97.85
5,088,982
2.15
236,302,793
560,193
Resolution 7
230,838,811
97.59
5,695,166
2.41
236,533,977
329,009
Resolution 8
235,036,711
99.45
1,292,616
0.55
236,329,327
533,659
*
Includes discretionary votes
**
Total votes cast do not include withheld votes
***
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against' any of the resolutions
For further information please contact:
Provexis plc
Dawson Buck, Chairman
Ian Ford, CEO & CFO
Tel: 07490 391888
enquiries@provexis.com
Allenby Capital Limited
Nick Naylor / Liz Kirchner
Tel: 020 3328 5656
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Provexis was founded in 1999 and is headquartered in Reading, Berkshire.
Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com and www.fruitflowplus.com.
Attachments
Original document
Permalink
Disclaimer
Provexis plc published this content on 04 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2019 12:31:09 UTC
Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
PROVEXIS PLC 
